COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 939905, 003B21A and 012M20A) for COVID-19 vaccination.     Previously administered products included for Drug use for unknown indication: Amoxicillin, Ceftriaxone and Vancomycin. Past adverse reactions to the above products included Allergy with Amoxicillin, Ceftriaxone and Vancomycin. Concurrent medical conditions included Allergic asthma (Allergy induced asthma (very mild)).   On 19-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In May 2022, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 31-May-2022 to 05-Jun-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) outcome was unknown.            No concomitant medications were reported. The patient had constant bitter taste in mouth, within 45 minutes of taking a dose. Sometimes fading for about an hour before the next dose. It did not affect taste of food. Diarrhea, not terribly severe, but uncomfortable and inconvenient. The patient did not take any other medications/products within 2 weeks of starting COVID-19 treatment.. No treatment medications were reported for diarrhea and dysgeusia.  Company comment: This spontaneous case concerns a female patient aged 44 years with no relevant medical history reported, who experienced the unexpected non serious AESI of Covid 19 on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series. It was reported that the patient was treated for covid infection with Pfizer drug from 31st May 2022 to 5th June 2022 for 6 days. Patient reported bitter taste after each dose lasting for hours and also Diarrhoea. No further details on clinical course, lab test results were reported. Patient had received initial two doses of Moderna vaccine at an interval of 28 days. The current pandemic situation of COVID 19 may remain as confounder. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.; Sender's Comments: This spontaneous case concerns a female patient aged 44 years with no relevant medical history reported, who experienced the unexpected non serious AESI of Covid 19 on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series. It was reported that the patient was treated for covid infection with Pfizer drug from 31st May 2022 to 5th June 2022 for 6 days. Patient reported bitter taste after each dose lasting for hours and also Diarrhoea. No further details on clinical course, lab test results were reported. Patient had received initial two doses of Moderna vaccine at an interval of 28 days. The current pandemic situation of COVID 19 may remain as confounder. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.